AVCRF Stock Chart & Stats
$0.02
$0.00(0.00%)
At close: 4:00 PM EDT
$0.02
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume11.00
Average Volume (3M)666.00
Market Cap
$5.42M
Enterprise Value$5.89
Total Cash (Recent Filing)$922.55K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.89
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding126,369,670
10 Day Avg. Volume0
30 Day Avg. Volume666
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)13.00
Price to Sales (P/S)9.49
P/FCF Ratio-5.60
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Zero DebtA debt-free balance sheet gives Avricore greater financial flexibility than a leveraged peer during a difficult operating period. It avoids mandatory interest and refinancing obligations, allowing management to direct available resources toward HealthTab adoption and operational recovery.
Prior Gross Profit ImprovementPositive gross profit and improved margins in 2023–2024 demonstrate that the underlying operating model has previously shown the ability to monetize demand. That history provides a foundation for recovery if revenue stabilizes and pharmacy testing activity returns to stronger levels.
Pharmacy-Based Digital PlatformHealthTab is embedded in community-pharmacy testing workflows rather than serving only as a standalone diagnostic product. Its combination of point-of-care testing, result management, and operational integration can support recurring platform use as participating pharmacies expand clinical services.
Bears Say
Severe Revenue DeteriorationThe sharp decline from the stronger 2023–2024 revenue base weakens evidence of sustained commercial traction. Very low trailing revenue can reduce operating scale, make fixed costs harder to absorb, and increase dependence on a successful rebound in pharmacy sites and testing volumes.
Deepening LossesNegative gross profit and widening net losses indicate that current revenue is not covering the economics of the business. Persistent operating deficits can constrain investment in HealthTab and force difficult funding or cost decisions, making profitability recovery a central execution requirement.
Negative Cash GenerationRecent negative operating and free cash flow show that Avricore is consuming cash rather than funding operations internally. If this pattern persists, available resources may decline and the company could face greater pressure to secure financing or reduce spending while pursuing growth.
Avricore Health News
AVCRF FAQ
What was Avricore Health Inc.’s price range in the past 12 months?
Avricore Health Inc. lowest stock price was $0.01 and its highest was $0.08 in the past 12 months.
What is Avricore Health Inc.’s market cap?
Avricore Health Inc.’s market cap is $5.42M.
When is Avricore Health Inc.’s upcoming earnings report date?
Avricore Health Inc.’s upcoming earnings report date is Nov 26, 2026 which is in 68 days.
How were Avricore Health Inc.’s earnings last quarter?
Avricore Health Inc. released its earnings results on Sep 01, 2026. The company reported -$0.002 earnings per share for the quarter.
Is Avricore Health Inc. overvalued?
According to Wall Street analysts Avricore Health Inc.’s price is currently Overvalued.
Does Avricore Health Inc. pay dividends?
Avricore Health Inc. does not currently pay dividends.
What is Avricore Health Inc.’s EPS estimate?
Avricore Health Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Avricore Health Inc. have?
Avricore Health Inc. has 126,369,670 shares outstanding.
What happened to Avricore Health Inc.’s price movement after its last earnings report?
Avricore Health Inc. reported an EPS of -$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Avricore Health Inc.?
Currently, no hedge funds are holding shares in AVCRF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Avricore Health Inc.
Avricore Health Inc. operates within Canada, specializing in health data management and point-of-care technological solutions. Their primary offering is HealthTab, a precise, laboratory-quality diagnostic testing system designed for use in pharmacies. This enterprise maintains key alliances with prominent organizations such as Shoppers Drug Marts and Abbott. Established in 1996 and headquartered in Vancouver, Canada, the company previously operated as Vanc Pharmaceuticals Inc., adopting its current name, Avricore Health Inc., in October 2018.
Technical Analysis
BioMark Diagnostics
―
Telo Genomics Corp
―
StageZero Life Sciences Ltd
―
―
PanGenomic Health, Inc. Class A
―